nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimethadione—CYP3A4—bone cancer	0.9	1	CbGaD
Trimethadione—Paramethadione—CYP3A4—bone cancer	0.00692	1	CrCbGaD
Trimethadione—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.00477	0.122	CbGpPWpGaD
Trimethadione—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—T—bone cancer	0.00412	0.106	CbGpPWpGaD
Trimethadione—Hepatosplenomegaly—Epirubicin—bone cancer	0.00381	0.0696	CcSEcCtD
Trimethadione—Hepatosplenomegaly—Doxorubicin—bone cancer	0.00352	0.0644	CcSEcCtD
Trimethadione—Lymphoma—Methotrexate—bone cancer	0.00191	0.035	CcSEcCtD
Trimethadione—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00157	0.0402	CbGpPWpGaD
Trimethadione—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00135	0.0347	CbGpPWpGaD
Trimethadione—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00129	0.0332	CbGpPWpGaD
Trimethadione—Hiccups—Cisplatin—bone cancer	0.00122	0.0223	CcSEcCtD
Trimethadione—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00121	0.031	CbGpPWpGaD
Trimethadione—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0011	0.0283	CbGpPWpGaD
Trimethadione—Gingival bleeding—Epirubicin—bone cancer	0.0011	0.0201	CcSEcCtD
Trimethadione—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00105	0.027	CbGpPWpGaD
Trimethadione—Gingival bleeding—Doxorubicin—bone cancer	0.00102	0.0186	CcSEcCtD
Trimethadione—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000903	0.0232	CbGpPWpGaD
Trimethadione—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000846	0.0217	CbGpPWpGaD
Trimethadione—Vaginal haemorrhage—Epirubicin—bone cancer	0.000844	0.0154	CcSEcCtD
Trimethadione—Irritability—Cisplatin—bone cancer	0.000843	0.0154	CcSEcCtD
Trimethadione—Albuminuria—Epirubicin—bone cancer	0.000837	0.0153	CcSEcCtD
Trimethadione—Vaginal haemorrhage—Doxorubicin—bone cancer	0.000781	0.0143	CcSEcCtD
Trimethadione—Albuminuria—Doxorubicin—bone cancer	0.000774	0.0142	CcSEcCtD
Trimethadione—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.000755	0.0194	CbGpPWpGaD
Trimethadione—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000726	0.0187	CbGpPWpGaD
Trimethadione—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000726	0.0187	CbGpPWpGaD
Trimethadione—Pancytopenia—Cisplatin—bone cancer	0.000725	0.0133	CcSEcCtD
Trimethadione—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000683	0.0175	CbGpPWpGaD
Trimethadione—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000674	0.0173	CbGpPWpGaD
Trimethadione—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000653	0.0168	CbGpPWpGaD
Trimethadione—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000628	0.0161	CbGpPWpGaD
Trimethadione—Aplastic anaemia—Methotrexate—bone cancer	0.000627	0.0115	CcSEcCtD
Trimethadione—Hiccups—Epirubicin—bone cancer	0.000625	0.0114	CcSEcCtD
Trimethadione—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000595	0.0153	CbGpPWpGaD
Trimethadione—Aplastic anaemia—Epirubicin—bone cancer	0.000587	0.0107	CcSEcCtD
Trimethadione—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000583	0.015	CbGpPWpGaD
Trimethadione—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000582	0.015	CbGpPWpGaD
Trimethadione—Hiccups—Doxorubicin—bone cancer	0.000578	0.0106	CcSEcCtD
Trimethadione—Lymphadenopathy—Methotrexate—bone cancer	0.000568	0.0104	CcSEcCtD
Trimethadione—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.00056	0.0144	CbGpPWpGaD
Trimethadione—Aplastic anaemia—Doxorubicin—bone cancer	0.000543	0.00993	CcSEcCtD
Trimethadione—Alopecia—Cisplatin—bone cancer	0.00054	0.00988	CcSEcCtD
Trimethadione—Lymphadenopathy—Epirubicin—bone cancer	0.000532	0.00973	CcSEcCtD
Trimethadione—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000531	0.0136	CbGpPWpGaD
Trimethadione—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00052	0.0133	CbGpPWpGaD
Trimethadione—Dermatitis exfoliative—Methotrexate—bone cancer	0.000514	0.0094	CcSEcCtD
Trimethadione—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000511	0.0131	CbGpPWpGaD
Trimethadione—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.000496	0.0127	CbGpPWpGaD
Trimethadione—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000494	0.0127	CbGpPWpGaD
Trimethadione—Ill-defined disorder—Cisplatin—bone cancer	0.000493	0.00903	CcSEcCtD
Trimethadione—Lymphadenopathy—Doxorubicin—bone cancer	0.000492	0.009	CcSEcCtD
Trimethadione—Dermatitis exfoliative—Epirubicin—bone cancer	0.000481	0.00879	CcSEcCtD
Trimethadione—Malaise—Cisplatin—bone cancer	0.00048	0.00878	CcSEcCtD
Trimethadione—Leukopenia—Cisplatin—bone cancer	0.000476	0.00871	CcSEcCtD
Trimethadione—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000474	0.0122	CbGpPWpGaD
Trimethadione—Irritability—Methotrexate—bone cancer	0.000463	0.00846	CcSEcCtD
Trimethadione—Diplopia—Epirubicin—bone cancer	0.000453	0.0083	CcSEcCtD
Trimethadione—Discomfort—Cisplatin—bone cancer	0.000447	0.00819	CcSEcCtD
Trimethadione—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000445	0.00814	CcSEcCtD
Trimethadione—Thrombocytopenia—Cisplatin—bone cancer	0.000425	0.00778	CcSEcCtD
Trimethadione—Diplopia—Doxorubicin—bone cancer	0.00042	0.00768	CcSEcCtD
Trimethadione—Eosinophilia—Methotrexate—bone cancer	0.000415	0.00759	CcSEcCtD
Trimethadione—Anorexia—Cisplatin—bone cancer	0.000414	0.00757	CcSEcCtD
Trimethadione—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.0004	0.0103	CbGpPWpGaD
Trimethadione—Pancytopenia—Methotrexate—bone cancer	0.000398	0.00728	CcSEcCtD
Trimethadione—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000392	0.0101	CbGpPWpGaD
Trimethadione—Neutropenia—Methotrexate—bone cancer	0.000392	0.00717	CcSEcCtD
Trimethadione—Paraesthesia—Cisplatin—bone cancer	0.00039	0.00713	CcSEcCtD
Trimethadione—Eosinophilia—Epirubicin—bone cancer	0.000388	0.0071	CcSEcCtD
Trimethadione—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000388	0.00996	CbGpPWpGaD
Trimethadione—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.000383	0.00983	CbGpPWpGaD
Trimethadione—Decreased appetite—Cisplatin—bone cancer	0.000377	0.0069	CcSEcCtD
Trimethadione—Drowsiness—Methotrexate—bone cancer	0.000373	0.00683	CcSEcCtD
Trimethadione—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.000372	0.00957	CbGpPWpGaD
Trimethadione—Pancytopenia—Epirubicin—bone cancer	0.000372	0.00681	CcSEcCtD
Trimethadione—Neutropenia—Epirubicin—bone cancer	0.000366	0.00671	CcSEcCtD
Trimethadione—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000365	0.00937	CbGpPWpGaD
Trimethadione—Eosinophilia—Doxorubicin—bone cancer	0.000359	0.00657	CcSEcCtD
Trimethadione—Feeling abnormal—Cisplatin—bone cancer	0.000358	0.00654	CcSEcCtD
Trimethadione—Weight decreased—Epirubicin—bone cancer	0.000355	0.00649	CcSEcCtD
Trimethadione—Epistaxis—Methotrexate—bone cancer	0.000352	0.00645	CcSEcCtD
Trimethadione—Drowsiness—Epirubicin—bone cancer	0.000349	0.00639	CcSEcCtD
Trimethadione—Agranulocytosis—Methotrexate—bone cancer	0.000348	0.00638	CcSEcCtD
Trimethadione—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000348	0.00893	CbGpPWpGaD
Trimethadione—Pancytopenia—Doxorubicin—bone cancer	0.000344	0.0063	CcSEcCtD
Trimethadione—Neutropenia—Doxorubicin—bone cancer	0.000339	0.00621	CcSEcCtD
Trimethadione—Haemoglobin—Methotrexate—bone cancer	0.000337	0.00617	CcSEcCtD
Trimethadione—Haemorrhage—Methotrexate—bone cancer	0.000335	0.00613	CcSEcCtD
Trimethadione—Hepatitis—Methotrexate—bone cancer	0.000335	0.00613	CcSEcCtD
Trimethadione—Epistaxis—Epirubicin—bone cancer	0.00033	0.00603	CcSEcCtD
Trimethadione—Weight decreased—Doxorubicin—bone cancer	0.000328	0.006	CcSEcCtD
Trimethadione—Agranulocytosis—Epirubicin—bone cancer	0.000326	0.00597	CcSEcCtD
Trimethadione—Drowsiness—Doxorubicin—bone cancer	0.000323	0.00592	CcSEcCtD
Trimethadione—Erythema multiforme—Methotrexate—bone cancer	0.000317	0.0058	CcSEcCtD
Trimethadione—Haemoglobin—Epirubicin—bone cancer	0.000315	0.00577	CcSEcCtD
Trimethadione—Hepatitis—Epirubicin—bone cancer	0.000314	0.00574	CcSEcCtD
Trimethadione—Haemorrhage—Epirubicin—bone cancer	0.000314	0.00574	CcSEcCtD
Trimethadione—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000314	0.00806	CbGpPWpGaD
Trimethadione—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000313	0.00803	CbGpPWpGaD
Trimethadione—Asthenia—Cisplatin—bone cancer	0.000311	0.0057	CcSEcCtD
Trimethadione—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00031	0.00795	CbGpPWpGaD
Trimethadione—Epistaxis—Doxorubicin—bone cancer	0.000305	0.00558	CcSEcCtD
Trimethadione—Agranulocytosis—Doxorubicin—bone cancer	0.000302	0.00552	CcSEcCtD
Trimethadione—Erythema multiforme—Epirubicin—bone cancer	0.000297	0.00543	CcSEcCtD
Trimethadione—Alopecia—Methotrexate—bone cancer	0.000296	0.00542	CcSEcCtD
Trimethadione—Haemoglobin—Doxorubicin—bone cancer	0.000292	0.00534	CcSEcCtD
Trimethadione—Haemorrhage—Doxorubicin—bone cancer	0.00029	0.00531	CcSEcCtD
Trimethadione—Hepatitis—Doxorubicin—bone cancer	0.00029	0.00531	CcSEcCtD
Trimethadione—Alopecia—Epirubicin—bone cancer	0.000277	0.00507	CcSEcCtD
Trimethadione—Vomiting—Cisplatin—bone cancer	0.000276	0.00505	CcSEcCtD
Trimethadione—Erythema multiforme—Doxorubicin—bone cancer	0.000274	0.00502	CcSEcCtD
Trimethadione—Rash—Cisplatin—bone cancer	0.000274	0.00501	CcSEcCtD
Trimethadione—Dermatitis—Cisplatin—bone cancer	0.000273	0.005	CcSEcCtD
Trimethadione—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000271	0.00696	CbGpPWpGaD
Trimethadione—Ill-defined disorder—Methotrexate—bone cancer	0.000271	0.00495	CcSEcCtD
Trimethadione—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000268	0.00687	CbGpPWpGaD
Trimethadione—Malaise—Methotrexate—bone cancer	0.000263	0.00482	CcSEcCtD
Trimethadione—Vertigo—Methotrexate—bone cancer	0.000262	0.0048	CcSEcCtD
Trimethadione—Leukopenia—Methotrexate—bone cancer	0.000261	0.00478	CcSEcCtD
Trimethadione—Nausea—Cisplatin—bone cancer	0.000258	0.00472	CcSEcCtD
Trimethadione—Alopecia—Doxorubicin—bone cancer	0.000257	0.00469	CcSEcCtD
Trimethadione—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000254	0.00653	CbGpPWpGaD
Trimethadione—Ill-defined disorder—Epirubicin—bone cancer	0.000253	0.00464	CcSEcCtD
Trimethadione—Malaise—Epirubicin—bone cancer	0.000246	0.00451	CcSEcCtD
Trimethadione—Discomfort—Methotrexate—bone cancer	0.000245	0.00449	CcSEcCtD
Trimethadione—Vertigo—Epirubicin—bone cancer	0.000245	0.00449	CcSEcCtD
Trimethadione—Leukopenia—Epirubicin—bone cancer	0.000244	0.00447	CcSEcCtD
Trimethadione—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000242	0.00622	CbGpPWpGaD
Trimethadione—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000239	0.00613	CbGpPWpGaD
Trimethadione—Ill-defined disorder—Doxorubicin—bone cancer	0.000234	0.00429	CcSEcCtD
Trimethadione—Thrombocytopenia—Methotrexate—bone cancer	0.000233	0.00427	CcSEcCtD
Trimethadione—Discomfort—Epirubicin—bone cancer	0.00023	0.0042	CcSEcCtD
Trimethadione—Malaise—Doxorubicin—bone cancer	0.000228	0.00417	CcSEcCtD
Trimethadione—Vertigo—Doxorubicin—bone cancer	0.000227	0.00415	CcSEcCtD
Trimethadione—Anorexia—Methotrexate—bone cancer	0.000227	0.00415	CcSEcCtD
Trimethadione—Leukopenia—Doxorubicin—bone cancer	0.000226	0.00414	CcSEcCtD
Trimethadione—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000221	0.00567	CbGpPWpGaD
Trimethadione—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00022	0.00564	CbGpPWpGaD
Trimethadione—Thrombocytopenia—Epirubicin—bone cancer	0.000218	0.00399	CcSEcCtD
Trimethadione—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000218	0.00559	CbGpPWpGaD
Trimethadione—Insomnia—Methotrexate—bone cancer	0.000215	0.00394	CcSEcCtD
Trimethadione—Paraesthesia—Methotrexate—bone cancer	0.000214	0.00391	CcSEcCtD
Trimethadione—Discomfort—Doxorubicin—bone cancer	0.000213	0.00389	CcSEcCtD
Trimethadione—Anorexia—Epirubicin—bone cancer	0.000212	0.00389	CcSEcCtD
Trimethadione—Somnolence—Methotrexate—bone cancer	0.000212	0.00387	CcSEcCtD
Trimethadione—Decreased appetite—Methotrexate—bone cancer	0.000207	0.00379	CcSEcCtD
Trimethadione—Fatigue—Methotrexate—bone cancer	0.000205	0.00376	CcSEcCtD
Trimethadione—Thrombocytopenia—Doxorubicin—bone cancer	0.000202	0.00369	CcSEcCtD
Trimethadione—Insomnia—Epirubicin—bone cancer	0.000202	0.00369	CcSEcCtD
Trimethadione—Paraesthesia—Epirubicin—bone cancer	0.0002	0.00366	CcSEcCtD
Trimethadione—Somnolence—Epirubicin—bone cancer	0.000198	0.00363	CcSEcCtD
Trimethadione—Anorexia—Doxorubicin—bone cancer	0.000197	0.0036	CcSEcCtD
Trimethadione—Feeling abnormal—Methotrexate—bone cancer	0.000196	0.00359	CcSEcCtD
Trimethadione—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000196	0.00504	CbGpPWpGaD
Trimethadione—Gastrointestinal pain—Methotrexate—bone cancer	0.000195	0.00356	CcSEcCtD
Trimethadione—CACNA1G—Axon guidance—MET—bone cancer	0.000194	0.00498	CbGpPWpGaD
Trimethadione—Decreased appetite—Epirubicin—bone cancer	0.000194	0.00355	CcSEcCtD
Trimethadione—Fatigue—Epirubicin—bone cancer	0.000192	0.00352	CcSEcCtD
Trimethadione—Abdominal pain—Methotrexate—bone cancer	0.000188	0.00345	CcSEcCtD
Trimethadione—Insomnia—Doxorubicin—bone cancer	0.000187	0.00341	CcSEcCtD
Trimethadione—Paraesthesia—Doxorubicin—bone cancer	0.000185	0.00339	CcSEcCtD
Trimethadione—Feeling abnormal—Epirubicin—bone cancer	0.000184	0.00336	CcSEcCtD
Trimethadione—Somnolence—Doxorubicin—bone cancer	0.000183	0.00335	CcSEcCtD
Trimethadione—Gastrointestinal pain—Epirubicin—bone cancer	0.000182	0.00334	CcSEcCtD
Trimethadione—Decreased appetite—Doxorubicin—bone cancer	0.000179	0.00328	CcSEcCtD
Trimethadione—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000179	0.00459	CbGpPWpGaD
Trimethadione—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000178	0.00458	CbGpPWpGaD
Trimethadione—Fatigue—Doxorubicin—bone cancer	0.000178	0.00325	CcSEcCtD
Trimethadione—Abdominal pain—Epirubicin—bone cancer	0.000176	0.00322	CcSEcCtD
Trimethadione—Asthenia—Methotrexate—bone cancer	0.000171	0.00313	CcSEcCtD
Trimethadione—Feeling abnormal—Doxorubicin—bone cancer	0.00017	0.00311	CcSEcCtD
Trimethadione—Gastrointestinal pain—Doxorubicin—bone cancer	0.000169	0.00309	CcSEcCtD
Trimethadione—Pruritus—Methotrexate—bone cancer	0.000169	0.00308	CcSEcCtD
Trimethadione—Abdominal pain—Doxorubicin—bone cancer	0.000163	0.00298	CcSEcCtD
Trimethadione—CACNA1G—Axon guidance—MMP2—bone cancer	0.000162	0.00416	CbGpPWpGaD
Trimethadione—Asthenia—Epirubicin—bone cancer	0.00016	0.00293	CcSEcCtD
Trimethadione—Pruritus—Epirubicin—bone cancer	0.000158	0.00289	CcSEcCtD
Trimethadione—Vomiting—Methotrexate—bone cancer	0.000151	0.00277	CcSEcCtD
Trimethadione—Rash—Methotrexate—bone cancer	0.00015	0.00275	CcSEcCtD
Trimethadione—Dermatitis—Methotrexate—bone cancer	0.00015	0.00275	CcSEcCtD
Trimethadione—Headache—Methotrexate—bone cancer	0.000149	0.00273	CcSEcCtD
Trimethadione—Asthenia—Doxorubicin—bone cancer	0.000148	0.00271	CcSEcCtD
Trimethadione—Pruritus—Doxorubicin—bone cancer	0.000146	0.00267	CcSEcCtD
Trimethadione—Vomiting—Epirubicin—bone cancer	0.000142	0.00259	CcSEcCtD
Trimethadione—Nausea—Methotrexate—bone cancer	0.000141	0.00259	CcSEcCtD
Trimethadione—Rash—Epirubicin—bone cancer	0.000141	0.00257	CcSEcCtD
Trimethadione—Dermatitis—Epirubicin—bone cancer	0.00014	0.00257	CcSEcCtD
Trimethadione—Headache—Epirubicin—bone cancer	0.00014	0.00256	CcSEcCtD
Trimethadione—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000139	0.00357	CbGpPWpGaD
Trimethadione—CACNA1G—Developmental Biology—MET—bone cancer	0.000138	0.00356	CbGpPWpGaD
Trimethadione—CACNA1G—Developmental Biology—CDK4—bone cancer	0.000138	0.00356	CbGpPWpGaD
Trimethadione—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000135	0.00347	CbGpPWpGaD
Trimethadione—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000133	0.00342	CbGpPWpGaD
Trimethadione—Nausea—Epirubicin—bone cancer	0.000132	0.00242	CcSEcCtD
Trimethadione—Vomiting—Doxorubicin—bone cancer	0.000131	0.0024	CcSEcCtD
Trimethadione—Rash—Doxorubicin—bone cancer	0.00013	0.00238	CcSEcCtD
Trimethadione—Dermatitis—Doxorubicin—bone cancer	0.00013	0.00238	CcSEcCtD
Trimethadione—Headache—Doxorubicin—bone cancer	0.000129	0.00236	CcSEcCtD
Trimethadione—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000124	0.00319	CbGpPWpGaD
Trimethadione—Nausea—Doxorubicin—bone cancer	0.000122	0.00224	CcSEcCtD
Trimethadione—CACNA1G—Axon guidance—MMP9—bone cancer	0.000122	0.00312	CbGpPWpGaD
Trimethadione—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000117	0.003	CbGpPWpGaD
Trimethadione—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000116	0.00297	CbGpPWpGaD
Trimethadione—CACNA1G—Developmental Biology—MMP2—bone cancer	0.000115	0.00297	CbGpPWpGaD
Trimethadione—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000115	0.00296	CbGpPWpGaD
Trimethadione—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000114	0.00293	CbGpPWpGaD
Trimethadione—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000113	0.00291	CbGpPWpGaD
Trimethadione—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000104	0.00268	CbGpPWpGaD
Trimethadione—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000103	0.00264	CbGpPWpGaD
Trimethadione—CYP2C8—Biological oxidations—GSTP1—bone cancer	9.98e-05	0.00256	CbGpPWpGaD
Trimethadione—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	9.85e-05	0.00253	CbGpPWpGaD
Trimethadione—CACNA1G—Axon guidance—EGFR—bone cancer	9.83e-05	0.00252	CbGpPWpGaD
Trimethadione—CYP2C9—Biological oxidations—CYP3A4—bone cancer	9.5e-05	0.00244	CbGpPWpGaD
Trimethadione—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	9.37e-05	0.00241	CbGpPWpGaD
Trimethadione—CYP2C19—Biological oxidations—GSTP1—bone cancer	8.91e-05	0.00229	CbGpPWpGaD
Trimethadione—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	8.79e-05	0.00226	CbGpPWpGaD
Trimethadione—CACNA1G—Developmental Biology—MMP9—bone cancer	8.68e-05	0.00223	CbGpPWpGaD
Trimethadione—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.27e-05	0.00212	CbGpPWpGaD
Trimethadione—CYP2C9—Biological oxidations—GSTP1—bone cancer	8.13e-05	0.00209	CbGpPWpGaD
Trimethadione—CYP2E1—Metabolism—NDUFA12—bone cancer	8.1e-05	0.00208	CbGpPWpGaD
Trimethadione—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	8.01e-05	0.00206	CbGpPWpGaD
Trimethadione—CACNA1G—Developmental Biology—EGFR—bone cancer	7.01e-05	0.0018	CbGpPWpGaD
Trimethadione—CYP2C8—Metabolism—NDUFA12—bone cancer	7e-05	0.0018	CbGpPWpGaD
Trimethadione—CYP2E1—Metabolism—NT5C3A—bone cancer	6.71e-05	0.00172	CbGpPWpGaD
Trimethadione—CYP2C19—Metabolism—NDUFA12—bone cancer	6.25e-05	0.0016	CbGpPWpGaD
Trimethadione—CYP2C8—Metabolism—NT5C3A—bone cancer	5.8e-05	0.00149	CbGpPWpGaD
Trimethadione—CYP2C9—Metabolism—NDUFA12—bone cancer	5.7e-05	0.00146	CbGpPWpGaD
Trimethadione—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.36e-05	0.00138	CbGpPWpGaD
Trimethadione—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.29e-05	0.00136	CbGpPWpGaD
Trimethadione—CYP2C19—Metabolism—NT5C3A—bone cancer	5.18e-05	0.00133	CbGpPWpGaD
Trimethadione—CYP2C9—Metabolism—NT5C3A—bone cancer	4.72e-05	0.00121	CbGpPWpGaD
Trimethadione—CYP3A4—Metabolism—NDUFA12—bone cancer	3.76e-05	0.000965	CbGpPWpGaD
Trimethadione—CYP3A4—Metabolism—NT5C3A—bone cancer	3.11e-05	0.000799	CbGpPWpGaD
Trimethadione—CYP2E1—Metabolism—ENO2—bone cancer	2.94e-05	0.000755	CbGpPWpGaD
Trimethadione—CYP2E1—Metabolism—DHFR—bone cancer	2.73e-05	0.0007	CbGpPWpGaD
Trimethadione—CYP2E1—Metabolism—GNA11—bone cancer	2.55e-05	0.000654	CbGpPWpGaD
Trimethadione—CYP2C8—Metabolism—ENO2—bone cancer	2.54e-05	0.000652	CbGpPWpGaD
Trimethadione—CYP2C8—Metabolism—DHFR—bone cancer	2.36e-05	0.000605	CbGpPWpGaD
Trimethadione—CYP2E1—Metabolism—CYP3A4—bone cancer	2.31e-05	0.000593	CbGpPWpGaD
Trimethadione—CYP2C19—Metabolism—ENO2—bone cancer	2.27e-05	0.000582	CbGpPWpGaD
Trimethadione—CYP2C8—Metabolism—GNA11—bone cancer	2.2e-05	0.000566	CbGpPWpGaD
Trimethadione—CYP2C19—Metabolism—DHFR—bone cancer	2.1e-05	0.00054	CbGpPWpGaD
Trimethadione—CYP2C9—Metabolism—ENO2—bone cancer	2.07e-05	0.000531	CbGpPWpGaD
Trimethadione—CYP2C8—Metabolism—CYP3A4—bone cancer	2e-05	0.000513	CbGpPWpGaD
Trimethadione—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.99e-05	0.00051	CbGpPWpGaD
Trimethadione—CYP2E1—Metabolism—GSTP1—bone cancer	1.98e-05	0.000507	CbGpPWpGaD
Trimethadione—CYP2C19—Metabolism—GNA11—bone cancer	1.97e-05	0.000505	CbGpPWpGaD
Trimethadione—CYP2C9—Metabolism—DHFR—bone cancer	1.92e-05	0.000493	CbGpPWpGaD
Trimethadione—CYP2C9—Metabolism—GNA11—bone cancer	1.79e-05	0.00046	CbGpPWpGaD
Trimethadione—CYP2C19—Metabolism—CYP3A4—bone cancer	1.78e-05	0.000458	CbGpPWpGaD
Trimethadione—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.77e-05	0.000455	CbGpPWpGaD
Trimethadione—CYP2C8—Metabolism—GSTP1—bone cancer	1.71e-05	0.000439	CbGpPWpGaD
Trimethadione—CYP2C9—Metabolism—CYP3A4—bone cancer	1.62e-05	0.000417	CbGpPWpGaD
Trimethadione—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.62e-05	0.000415	CbGpPWpGaD
Trimethadione—CYP2C19—Metabolism—GSTP1—bone cancer	1.52e-05	0.000391	CbGpPWpGaD
Trimethadione—CYP2C9—Metabolism—GSTP1—bone cancer	1.39e-05	0.000357	CbGpPWpGaD
Trimethadione—CYP3A4—Metabolism—ENO2—bone cancer	1.36e-05	0.00035	CbGpPWpGaD
Trimethadione—CYP3A4—Metabolism—DHFR—bone cancer	1.26e-05	0.000325	CbGpPWpGaD
Trimethadione—CYP3A4—Metabolism—GNA11—bone cancer	1.18e-05	0.000304	CbGpPWpGaD
Trimethadione—CYP2E1—Metabolism—PTGS2—bone cancer	1.02e-05	0.000263	CbGpPWpGaD
Trimethadione—CYP3A4—Metabolism—GSTP1—bone cancer	9.17e-06	0.000235	CbGpPWpGaD
Trimethadione—CYP2C8—Metabolism—PTGS2—bone cancer	8.85e-06	0.000227	CbGpPWpGaD
Trimethadione—CYP2C19—Metabolism—PTGS2—bone cancer	7.9e-06	0.000203	CbGpPWpGaD
Trimethadione—CYP2C9—Metabolism—PTGS2—bone cancer	7.2e-06	0.000185	CbGpPWpGaD
Trimethadione—CYP3A4—Metabolism—PTGS2—bone cancer	4.75e-06	0.000122	CbGpPWpGaD
